• Home
  • Blog
  • Events
  • Project Portfolio
  • Archive
  • Resources
  • Contact Us
WREN
  • Home
  • Blog
  • Events
  • Project Portfolio
  • Archive
  • Resources
  • Contact Us
Picture
Picture
Dr Tom Cromarty
Editor
Interests: Paediatric Emergency Medicine, Medical Engagement and Leadership, Simulation, Quality Improvement, Research 
Twitter: 
@Tomcromarty
Welsh Research and Education Network

WREN Blog

Hot topics in research and medical education, in Wales and beyond
Picture
​Dr Celyn Kenny
​Editor
Interests: Neonates, Neurodevelopment, Sepsis, Media and Broadcasting
Twitter: @Celynkenny
Picture
Dr Annabel Greenwood
Editor
Interests: Neonatology, Paediatric Emergency Medicine, Medical Education, Research, Quality Improvement
​Twitter: @an_greenwood

Archives
​

November 2020
June 2020
May 2020
April 2020
March 2020
February 2020
January 2020
December 2019
November 2019
October 2019
September 2019
August 2019
July 2019
June 2019
May 2019
April 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
May 2018
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017

Categories

All
A Day In The Life Of ...
Conference
Education
General
Global Health
Journal Club
Medical Leadership
News
Public Health
Research
Simulation
Trials
Wales

ECUSTEC

1/3/2018

1 Comment

 
Picture
‘Eculizumab in Shiga-Toxin producing E. Coli Haemolytic Uraemic Syndrome: A Randomised, Double-Blind, Placebo-Controlled Trial’
This is a trial currently recruiting on the Paediatric Nephrology Unit at UHW

Aim of trial:
To assess whether Eculizumab reduces the severity of Shiga-toxin producing Ecoli Haemolytic Uraemic Syndrome (STEC HUS) in children and young people
 
Background:
  • HUS - Commonest cause of intrinsic acute kidney injury in children
  • Classical triad: Microangiopathic haemolytic anaemia, thrombocytopenia, acute kidney injury
  • 95% of HUS cases occur post infection with Shiga-toxin producing E. coli (STEC) – ‘Typical’ HUS
  • ~ 120 cases/year in UK
  • 2-3% mortality rate, 50-60% of children require dialysis
  • Long term complications in ~30% of survivors e.g. CKD, permanent brain injury  
 
 
What is Eculizumab?
  • A monoclonal antibody that inhibits complement
  • Incredibly expensive
  • Already in use for the treatment of Atypical HUS
  • Previous studies into the use of Eculizumab in STEC-HUS have generated variable findings, with no objective evidence of efficacy or safety in children.  There has been no prospective, controlled trial in STEC-HUS
 
 
Primary Research Objective:
To determine whether the severity of STEC HUS is less in those given Ecu compared with those given placebo, in children aged 6m-18 years
​
-Clinical Severity Score assigned at day 60
 
Secondary Objectives:
i)To assess the safety of Ecu in STEC HUS
ii)To determine whether the incidence of CKD following STEC HUS is less in those receiving Ecu compared with those receiving placebo
iii)To evaluate the cost-effectiveness of administration of Ecu in STEC HUS from the perspective of the NHS
 
 
 
Inclusion Criteria
  • Age 6m to <19y
  • Weight ≥5kg
  • Diagnosis of HUS
                                                  - MAHA
                                                  - Thrombocytopaenia
                                                  - AKI​
  • EITHER Reported Diarrhoea within 14d prior to diagnosis​ OR stool culture/shiga toxin PCR/STEC serology result indicating STEC in the patient or household contact within 14 days prior to diagnosis of HUS
  • Patient to receive Eculizumab within 36hours of arrival to renal unit
 
Exclusion Criteria
  • Family history of aHUS
  • Previous episode of HUS
  • Known pre-existing eGFR <90ml/min/1.73m2
  • Known/suspected pneumococcal infection or meningococcal infection
  • Patient taking a drug known to be a/w HUS
  • Pregnancy
  • Malignancy
 
 
 
Active arm: Standard therapy + 1st dose Ecu Day 1, & 2nd dose Ecu Day 8
 
Control arm: Standard therapy + 1st dose placebo Day 1, & 2nd dose placebo Day 8
NB:  The trial contains an internal pilot phase of 18m (12m recruitment, 6m follow-up), the purpose of which is to determine whether the substantive trial will continue.
For further information please contact:
​ Jennifer Muller, Paediatric Research Specialist Nurse (CYARU)

Jennifer.muller@wales.nhs.uk
Annabel Greenwood
Paediatric ST3
1 Comment
https://research-paper-writing-services.net/meldaresearch-com/ link
7/11/2018 03:52:25 am

Research papers are hard to get, but if you need them you can look them on https://research-paper-writing-services.net/meldaresearch-com/. It will be great and people will know about it. It's what they tell me.

Reply



Leave a Reply.

    Editors

    Dr Annabel Greenwood
    Dr Tom Cromarty
    ​Dr Celyn Kenny
    Dr Davide Paccagnella

    Archives

    November 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017

    Categories

    All
    A Day In The Life Of ...
    Conference
    Education
    General
    Global Health
    Journal Club
    Medical Leadership
    News
    Public Health
    Research
    Simulation
    Trials
    Wales

    RSS Feed

Last Updated 17th November 2020
​@WRENpaeds

Picture
Proudly powered by Weebly
  • Home
  • Blog
  • Events
  • Project Portfolio
  • Archive
  • Resources
  • Contact Us